June 9th 2023
Review top news and interview highlights from the week ending June 9, 2023.
European Application Submitted for Cilta-cel in Relapsed and Lenalidomide-Refractory Myeloma
May 30th 2023The Type II variation application for ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma is supported by data from the phase 3 CARTITUDE-4 trial.
Bringing HLA-A*02-directed CAR T to Solid Tumor Care With the EVEREST-1 Trial
May 22nd 2023Diane M. Simeone, MD, discussed the phase 1/2 EVEREST-1 trial, which seeks to assess the novel CAR T-cell therapy A2B530 in patients with solid tumors—hopefully progressing one-and-done engineered therapies in this population.